Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

Affiliations

¹ General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.

^# Contributed equally.

Published Erratum

Qingyue Zeng et al. Front Endocrinol (Lausanne). 2024.

. 2024 Mar 14:15:1342543.

doi: 10.3389/fendo.2024.1342543. eCollection 2024.

¹ General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fendo.2023.1214334.].

Keywords: dual agonists; glucagon-like peptide-1 receptor agonists; incretin based therapy; obesity; tirzepatide; type 2 diabetes.

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Zeng Q, et al. Front Endocrinol (Lausanne). 2023 Oct 16;14:1214334. doi: 10.3389/fendo.2023.1214334. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37908750 Free PMC article.